Advertisement
Advertisement


A sudden drug export bonanza for Italy

The dramatic increase in exports surprised analysts, but Robin Brooks, chief economist and managing director at the Institute of International Finance (IIF), shared an analysis showing that the change was entirely due to UDCA.

Advertisement

Data shared with Quartz by Jonathan Pingle, the IIF’s global macroeconomic researcher, shows that exports from Italy to China in sectors outside pharmaceuticals have declined slightly.

Advertisement

UDCA’s potential for treating covid was serendipitously discovered during unrelated research, when scientists found that the drug slowed conversion of an enzyme believed to facilitate the entrance of the virus into an organism. But no trials have confirmed that it works, and even if it did, researchers stress that it could not be considered a viable alternative to vaccines.

Yet in China, where people feel vulnerable to covid in the absence of foreign vaccines, UDCA—a cheap drug that sells over the counter in Italy for €9 ($10) per 20 capsules—is in high demand.

Advertisement

Local manufacturers Xuantai Pharma and New China Pharma saw their share prices jump by 53% and 69% respectively, the week the Nature study was published, and imports surged. Enter ICE Pharma, based in Reggio Emilia, Italy, the world’s largest producer of UDCA.

If sales of the drug have skyrocketed, they’re already showing signs of a slowdown. Preliminary data from Banca d’Italia reveals that exports to China fell from €3 billion in February to €1.8 billion in March.

📬 Sign up for the Daily Brief

Our free, fast, and fun briefing on the global economy, delivered every weekday morning.